Tardive Dyskinesia Therapeutics Global Market Report 2025

The tardive dyskinesia therapeutics market size has grown strongly in recent years. It will grow from $2.9 billion in 2024 to $3.12 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. This growth during the historical period can be linked to an increasing prevalence of tardive dyskinesia, a rising global population affected by schizophrenia and bipolar disorder, better awareness and improved diagnostic practices, heightened use of both atypical and typical antipsychotic medications, and an expanding aging population.

The tardive dyskinesia therapeutics market size is expected to see strong growth in the next few years. It will grow to $4.11 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. Factors contributing to this anticipated growth include the escalating burden of mental health disorders, a surge in R&D initiatives, heightened investments from pharmaceutical firms, an increasing inclination towards personalized treatment approaches, and enhanced healthcare infrastructure. Key trends projected for this period include strategic alliances between pharmaceutical companies and research institutions, development of long-acting formulations, introduction of generic options, regulatory benefits like orphan drug status, and innovations in drug delivery technologies.

The rising prevalence of mental health disorders is expected to drive the growth of the tardive dyskinesia therapeutics market in the coming years. Mental health disorders, which impact a person’s thoughts, emotions, behaviors, or daily functioning, are increasing due to growing social isolation. The widespread adoption of digital communication and the demands of fast-paced lifestyles have reduced meaningful face-to-face interactions, leading to heightened feelings of loneliness and emotional strain. Tardive dyskinesia therapeutics play a crucial role in supporting individuals with mental health conditions by managing involuntary movement symptoms resulting from long-term antipsychotic use. This, in turn, enhances treatment adherence and overall quality of life. For example, in 2024, the National Alliance on Mental Illness reported that among U.S. individuals aged 18-44, psychosis spectrum and mood disorders are responsible for nearly 600,000 hospitalizations annually. As a result, the increasing occurrence of mental health disorders is a significant factor propelling the tardive dyskinesia therapeutics market.

Leading companies in the tardive dyskinesia therapeutics market are concentrating on the development of advanced products such as once-daily treatment options to ensure more consistent drug levels in the body. These once-daily treatments simplify medication schedules and enhance patient compliance. In May 2024, Teva Pharmaceutical Industries Limited, an Israel-based biopharmaceutical company, received U.S. FDA approval for AUSTEDO XR tablets, designed for adults with tardive dyskinesia and chorea associated with Huntington’s disease. AUSTEDO XR provides effective symptom control through a single daily dose and is now offered in four strengths: 30 mg, 36 mg, 42 mg, and 48 mg. The formulation’s efficacy has been validated through pivotal clinical trials, emphasizing its role in improving convenience and adherence in patient care.

In February 2024, Teva Pharmaceutical Industries Limited entered a partnership with Jiangsu Nhwa Pharmaceutical Co. Ltd. to promote and distribute AUSTEDO in China. This collaboration leverages Nhwa’s established presence in China’s neuropsychiatric health sector to broaden access to AUSTEDO. The drug is recognized as the first VMAT2 inhibitor approved by the U.S. FDA for treating tardive dyskinesia and Huntington’s disease-related chorea in adults. Jiangsu Nhwa Pharmaceutical Co. Ltd. is a pharmaceutical company based in China.

Major players in the tardive dyskinesia therapeutics market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lundbeck A/S, Amneal Pharmaceuticals Inc., Lupin Pharmaceuticals Inc., Neurocrine Biosciences Inc., Luye Pharma Ltd., Lannett Co. Inc., SteriMax Inc., Zydus Cadila Healthcare Ltd., Adamas Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, SOM Biotech Ltd., Addex Therapeutics.

North America was the largest region in the tardive dyskinesia therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tardive dyskinesia therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tardive dyskinesia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tardive dyskinesia therapeutics are treatments aimed at alleviating or controlling the involuntary, repetitive movements associated with this neurological condition. These therapies focus on addressing the neurological disruptions commonly linked to long-term use of specific medications. Their primary objective is to enhance the patient's quality of life by decreasing the intensity and occurrence of motor symptoms, improving functional capabilities, and preventing chronic complications.

Key medications in the tardive dyskinesia therapeutics market include deutetrabenazine, valbenazine, and others. Deutetrabenazine, a vesicular monoamine transporter type 2 (VMAT2) inhibitor, is specifically utilized to manage involuntary movements related to tardive dyskinesia. It is available in various forms such as solid dosage (tablets and capsules), liquid forms, and injections. The drug is applied in cases of antipsychotic-induced tardive dyskinesia, other drug-induced types, and idiopathic tardive dyskinesia. It is administered across multiple end-user environments including hospitals, clinics, specialty treatment centers, and homecare settings.

The tardive dyskinesia therapeutics market research report is one of a series of new reports that provides tardive dyskinesia therapeutics market statistics, including tardive dyskinesia therapeutics industry global market size, regional shares, competitors with a tardive dyskinesia therapeutics market share, detailed tardive dyskinesia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the tardive dyskinesia therapeutics industry. This tardive dyskinesia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tardive dyskinesia therapeutics market consists of revenues earned by entities by providing services such as drug discovery, clinical trial management, formulation services, and pharmacovigilance. The market value includes the value of related goods sold by the service provider or included within the service offering. The tardive dyskinesia therapeutics market also includes sales of adjunctive medications, patient monitoring devices, drug delivery systems, and screening tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.